Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Dog Diseases | 4 | 2024 | 86 | 1.430 |
Why?
|
| Cat Diseases | 2 | 2018 | 27 | 0.970 |
Why?
|
| Prednisone | 2 | 2024 | 224 | 0.720 |
Why?
|
| Doxorubicin | 2 | 2024 | 401 | 0.650 |
Why?
|
| Mammary Neoplasms, Animal | 1 | 2018 | 35 | 0.540 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2018 | 140 | 0.530 |
Why?
|
| Cyclophosphamide | 2 | 2024 | 270 | 0.520 |
Why?
|
| Lymphoma, B-Cell | 1 | 2018 | 140 | 0.510 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2018 | 193 | 0.510 |
Why?
|
| Mastectomy | 1 | 2018 | 184 | 0.490 |
Why?
|
| Veterinary Medicine | 1 | 2014 | 11 | 0.430 |
Why?
|
| Dogs | 6 | 2024 | 458 | 0.410 |
Why?
|
| Antineoplastic Agents | 3 | 2014 | 2214 | 0.380 |
Why?
|
| T-Lymphocytes, Regulatory | 2 | 2011 | 409 | 0.330 |
Why?
|
| Adenocarcinoma | 1 | 2018 | 925 | 0.330 |
Why?
|
| Soft Tissue Neoplasms | 1 | 2011 | 131 | 0.310 |
Why?
|
| Clinical Trials as Topic | 1 | 2014 | 1061 | 0.290 |
Why?
|
| Sarcoma | 1 | 2011 | 207 | 0.280 |
Why?
|
| Cats | 2 | 2018 | 231 | 0.230 |
Why?
|
| Vincristine | 1 | 2024 | 142 | 0.200 |
Why?
|
| Lymphoma | 1 | 2024 | 237 | 0.180 |
Why?
|
| Chemoembolization, Therapeutic | 1 | 2022 | 89 | 0.170 |
Why?
|
| Neoplasms | 1 | 2014 | 2906 | 0.140 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2022 | 372 | 0.140 |
Why?
|
| Animals | 7 | 2024 | 38030 | 0.120 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2018 | 969 | 0.120 |
Why?
|
| Liver Neoplasms | 1 | 2022 | 776 | 0.120 |
Why?
|
| Drug Therapy, Combination | 1 | 2018 | 1044 | 0.110 |
Why?
|
| Pets | 1 | 2014 | 26 | 0.110 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2024 | 1963 | 0.100 |
Why?
|
| Retrospective Studies | 3 | 2024 | 17291 | 0.090 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2018 | 1149 | 0.080 |
Why?
|
| Treatment Outcome | 3 | 2024 | 11772 | 0.080 |
Why?
|
| Immunophenotyping | 1 | 2011 | 319 | 0.080 |
Why?
|
| Osteosarcoma | 1 | 2010 | 82 | 0.080 |
Why?
|
| Neovascularization, Pathologic | 1 | 2011 | 286 | 0.080 |
Why?
|
| Biopsy | 1 | 2011 | 1082 | 0.070 |
Why?
|
| Flow Cytometry | 1 | 2011 | 1162 | 0.060 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2011 | 2028 | 0.060 |
Why?
|
| Prospective Studies | 2 | 2024 | 8057 | 0.060 |
Why?
|
| Pilot Projects | 1 | 2011 | 1891 | 0.060 |
Why?
|
| Lomustine | 1 | 2024 | 17 | 0.050 |
Why?
|
| Asparaginase | 1 | 2024 | 32 | 0.050 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2010 | 919 | 0.050 |
Why?
|
| Alanine | 1 | 2024 | 169 | 0.050 |
Why?
|
| Purines | 1 | 2024 | 187 | 0.050 |
Why?
|
| Female | 3 | 2024 | 78845 | 0.050 |
Why?
|
| Absorbable Implants | 1 | 2022 | 38 | 0.050 |
Why?
|
| Microspheres | 1 | 2022 | 142 | 0.040 |
Why?
|
| Paclitaxel | 1 | 2022 | 257 | 0.040 |
Why?
|
| Cohort Studies | 1 | 2011 | 6013 | 0.040 |
Why?
|
| Quality of Life | 1 | 2011 | 3204 | 0.040 |
Why?
|
| Polymers | 1 | 2022 | 485 | 0.030 |
Why?
|
| Disease Progression | 1 | 2024 | 2864 | 0.030 |
Why?
|
| Male | 2 | 2024 | 72843 | 0.030 |
Why?
|
| Predictive Value of Tests | 1 | 2010 | 2121 | 0.010 |
Why?
|
| Humans | 1 | 2022 | 145475 | 0.000 |
Why?
|